Citi: Maintains CRISPR Therapeutics (CRSP.US) rating, adjusted from buy to buy rating, and adjusted the target price from $89.00 to $84.00.
花旗：维持CRISPR Therapeutics(CRSP.US)评级，由买入调整至买入评级, 目标价由89.00美元调整至84.00美元。
Citi: Maintains CRISPR Therapeutics (CRSP.US) rating, adjusted from buy to buy rating, and adjusted the target price from $89.00 to $84.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.